4 December 2018 - - US-based Generex Biotechnology Corp. (OTCMKTS: GNBT) has appointed Anthony J. Dolisi as Generex Chief Commercial officer and Michelle Starr as Generex chief marketing officer, the company said.

The two executives join the corporate executive team of Generex following the acquisition of Olaregen Therapeutix, where they will focus on the commercial launch of Excellagen, a regenerative collagen gel matrix, which is cleared by FDA for 17 indications, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second- degree burns, and skin tears) and draining wounds.

Dolisi has built a 24+ year career in the industry as a senior executive and business leader with fortune 500 companies including American Home Products, Glaxo SmithKline, Agouron, Pfizer, and Johnson and Johnson.

Dolisi is a sales, commercial and channel expert with: IDN, 340B, MCO, PBM, Specialty SPP LTC, State/ Federal government, Reimbursement /MACs, PAP / PSP / HUB. Dolisi is able to combine both commercial sales and clinical expertise.

He made his mark by building multi-m-dollar businesses, igniting growth in business lines, devising innovative differentiated product strategies, and spurring company growth through creative and comprehensive portfolio strategies.

Dolisi will lead in all efforts to commercialize the products, develop sales structures to effectively impact the market, and will be responsible for oversight of all commercial sectors of the company.

Starr has had a highly accomplished career in medical communications and strategic planning in the pharmaceutical and biotechnology industries for over 25 years.

Her experience spans several therapeutic categories including all aspects of cardiovascular disease, neuroscience, osteoarthritis, rheumatoid arthritis, ophthalmology, gastrointestinal diseases, and inflammation.

She has designed initiatives to create disease awareness for first in-class/category products, as well as previously untreated disease states.

In addition, Michelle has also developed and retained long-standing relationships with Global Opinion Leaders in several therapeutic categories. Michelle started BioDialogue with a focus on early- and clinical-stage companies where she applied her experience, skills, and competencies in their development of products from proof of concept through commercialization.

The goal of the company was to bring together early in the process, all stakeholders including companies, physicians, regulatory/payers and patients to ensure not only approval of products but market access, physician adoption, and patient advocacy.

Michelle will be responsible for creating an effective communications strategy targeting the viable end users and creating a universal product message to be utilized with all key products.

Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical devices, and pharmaceutical development.